Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma.

Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, Davies L, Brock C, Bower M, Gazzard B.

Int J Cancer. 2004 Feb 10;108(4):631-3.

2.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B.

AIDS. 2003 Jul 25;17(11):F17-22.

PMID:
12853764
3.

Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.

Lebbé C, Blum L, Pellet C, Blanchard G, Vérola O, Morel P, Danne O, Calvo F.

AIDS. 1998 May 7;12(7):F45-9.

PMID:
9619797
4.

Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy.

Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vázquez García E, Martínez Vázquez C.

Oral Oncol. 1998 May;34(3):236-8.

PMID:
9692061
5.

Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.

Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, Vernazza PL.

AIDS. 2004 Apr 9;18(6):955-7. No abstract available.

PMID:
15060447
6.

Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.

Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F.

HIV Med. 2012 Mar;13(3):166-71. doi: 10.1111/j.1468-1293.2011.00955.x. Epub 2011 Nov 24.

7.

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, Zucman D, Rouveix E, Saiag P.

AIDS. 2000 May 26;14(8):987-93.

PMID:
10853980
8.

[HIV protease inhibitors for the treatment of Kaposi's sarcoma].

Grosso G, Sgadari C, Barillari G, Toschi E, Bacigalupo I, Carlei D, Palladino C, Baccarini S, Malavasi L, Moracci G, Leone P, Chiozzini C, Monini P, Ensoli B.

Recenti Prog Med. 2003 Feb;94(2):69-74. Review. Italian.

PMID:
12908373
9.

Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.

Cattelan AM, Calabrò ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L.

J Natl Cancer Inst Monogr. 2001;(28):44-9.

PMID:
11158206
11.

Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.

Carleo MA, Di Martino F, Del Giudice A, Gargiulo M, Parrella G, Rosario P, Sangiovanni V, Viglietti R, Esposito V, Chirianni A.

In Vivo. 2015 Jan-Feb;29(1):133-6.

PMID:
25600542
12.

The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.

Fumagalli L, Zucchetti M, Parisi I, Viganò MG, Zecca B, Careddu A, D'Incalci M, Lazzarin A.

Cancer Chemother Pharmacol. 2000;45(6):495-501.

PMID:
10854138
14.

Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study.

Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechère M.

J Am Acad Dermatol. 1998 Apr;38(4):594-8.

PMID:
9555800
15.

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.

Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, Meenhorst PL, Inghels M, Mulder JW, Beijnen JH.

Cancer Chemother Pharmacol. 1999;43(6):516-9.

PMID:
10321513
16.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD.

AIDS. 2004 Nov 19;18(17):2277-84.

PMID:
15577540
18.

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.

Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L.

Eur J Cancer. 1999 Dec;35(13):1809-15.

PMID:
10673996
19.

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

Floridia M, Tomino C, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Amici R, Giannini G, Galluzzo CM, Andreotti M, Seeber AC, Ammassari A, Cingolani A, Lazzarin A, Scalise G, Cargnel A, Suter F, Milazzo F, Pastore G, Moroni M, Ciammarughi R, Pini R, Carosi G, D'Amato C, Contu L, Concia E, Bonazzi L, Aiuti F, Vigevani G, Vella S; ISS-IP1 Clinical Investigators.

AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1809-20.

PMID:
11118067
20.

Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.

Jung C, Bogner JR, Goebel F.

Eur J Med Res. 1998 Sep 17;3(9):439-42.

PMID:
9737891

Supplemental Content

Support Center